Jones Financial Companies
BCRX icon

Jones Financial Companies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jones Financial Companies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Buy
17,894
+1,012
+6% +$9.15K ﹤0.01% 2630
2026
Q1 		$158K Buy
16,882
+14,682
+667% +$114K ﹤0.01% 2483
2025
Q4 		$17.2K Buy
2,200
+717
+48% +$5.18K ﹤0.01% 3003
2025
Q3 		$11.3K Buy
1,483
+283
+24% +$2.36K ﹤0.01% 3034
2025
Q2 		$11.2K Sell
1,200
-50
-4% -$466 ﹤0.01% 2826
2025
Q1 		$9.82K Buy
1,250
+1,050
+525% +$8.47K ﹤0.01% 2712
2024
Q4 		$1.5K Buy
+200
New +$1.52K ﹤0.01% 3068
2022
Q2 		– Sell
-400
Closed -$7K – 727
2022
Q1 		$7K Buy
+400
New +$6.42K ﹤0.01% 540

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jones Financial Companies's BCRX Position: Q2 2026 in Review

Jones Financial Companies increased its BioCryst Pharmaceuticals (BCRX) stake by 6% in Q2 2026, buying an estimated $9.15K and bringing the position to 17,894 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Jones Financial Companies first reported a position in BCRX in Q1 2022 and has held it in 8 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Jones Financial Companies held 17,894 shares of BioCryst Pharmaceuticals worth $178K as of Q2 2026.
  • Jones Financial Companies bought 1,012 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $9.15K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2630 holding.
  • Jones Financial Companies first reported a position in BioCryst Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.